Distler, Jörg HW; Kuwana, Masataka; Assassi, Shervin; Denton, Christopher P; (2025) Emerging therapies for the treatment of systemic sclerosis. Nature Reviews Rheumatology , 21 pp. 612-625. 10.1038/s41584-025-01294-x.

Text Emerging therapies for the treatment of systemic sclerosis-NRR reprint 2025 for UCL upload.pdf - Accepted Version Access restricted to UCL open access staff until 9 March 2026. Download (391kB)

Abstract

Systemic sclerosis (SSc) is an autoimmune disease in which fibrotic, vascular, autoimmune and fibrotic mechanisms synergize to promote disease progression. SSc is associated with high morbidity and mortality, primarily owing to fibrotic tissue remodelling and subsequent organ failure. Despite progress with the approval of novel therapies, mortality remains high; approximately half of the people diagnosed with SSc will succumb to disease. This statistic highlights the considerable need for novel, effective therapies. Indeed, SSc has become a disease with very active drug development. Numerous drugs with different modes of actions are currently evaluated in or are about to enter clinical trials in SSc. These clinical trials provide hope for effectively slowing or even halting the progression of fibrosis and thereby further improving outcomes for patients with SSc.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item